232 related articles for article (PubMed ID: 35184645)
1. Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome.
Hao Y; Wei M; Zhang N; Zhang X
Bioengineered; 2022 Mar; 13(3):5467-5479. PubMed ID: 35184645
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist.
Jones B; Burade V; Akalestou E; Manchanda Y; Ramchunder Z; Carrat G; Nguyen-Tu MS; Marchetti P; Piemonti L; Leclerc I; Thennati R; Vilsboll T; Thorens B; Tomas A; Rutter GA
Diabetes Obes Metab; 2022 Nov; 24(11):2090-2101. PubMed ID: 35676825
[TBL] [Abstract][Full Text] [Related]
3. Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists.
Hinds CE; Peace E; Chen S; Davies I; El Eid L; Tomas A; Tan T; Minnion J; Jones B; Bloom SR
Diabetes Obes Metab; 2024 Jan; 26(1):65-77. PubMed ID: 37795639
[TBL] [Abstract][Full Text] [Related]
4. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
[TBL] [Abstract][Full Text] [Related]
5. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
[TBL] [Abstract][Full Text] [Related]
6. Targeting GLP-1 receptor trafficking to improve agonist efficacy.
Jones B; Buenaventura T; Kanda N; Chabosseau P; Owen BM; Scott R; Goldin R; Angkathunyakul N; Corrêa IR; Bosco D; Johnson PR; Piemonti L; Marchetti P; Shapiro AMJ; Cochran BJ; Hanyaloglu AC; Inoue A; Tan T; Rutter GA; Tomas A; Bloom SR
Nat Commun; 2018 Apr; 9(1):1602. PubMed ID: 29686402
[TBL] [Abstract][Full Text] [Related]
7. Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents.
Yang Q; Zhou F; Tang X; Wang J; Feng H; Jiang W; Jin L; Jiang N; Yuan Y; Han J; Yan Z
Eur J Med Chem; 2022 Apr; 233():114214. PubMed ID: 35231829
[TBL] [Abstract][Full Text] [Related]
8. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
9. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin JA
Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
[TBL] [Abstract][Full Text] [Related]
12. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
13. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.
Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK
Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049
[TBL] [Abstract][Full Text] [Related]
14. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
[TBL] [Abstract][Full Text] [Related]
15. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
17. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F
Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366
[TBL] [Abstract][Full Text] [Related]
18. Engineering a potent and long-acting GLP-1/Y
Xu J; Wang S; Wu H; Chen D; Han J; Lin Q
Peptides; 2023 Nov; 169():171073. PubMed ID: 37536423
[TBL] [Abstract][Full Text] [Related]
19. Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.
Cai X; Li C; Zhou J; Dai Y; Avraham Y; Sun L; Liu C; Tong J; Wang Y; Bi X; He L; Huang W; Qian H
Bioorg Chem; 2020 Jan; 95():103538. PubMed ID: 31901754
[TBL] [Abstract][Full Text] [Related]
20. Stapled and
Chen X; Fu J; Zhou F; Yang Q; Wang J; Feng H; Jiang W; Jin L; Tang X; Jiang N; Yin J; Han J
J Med Chem; 2020 Nov; 63(21):12595-12613. PubMed ID: 33125843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
